Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duell, P. B.
Right arrow Articles by Bierman, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duell, P. B.
Right arrow Articles by Bierman, E. L.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 40, Issue 3 377-384, Copyright © 1991 by American Diabetes Association


ARTICLES

Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux

PB Duell, JF Oram and EL Bierman
Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle.

Previous studies have shown that nonenzymatic glycosylation of high-density lipoprotein (HDL) inhibits high-affinity binding to cultured cells and the candidate HDL-receptor protein. Because binding of HDL to its receptor is required for HDL-receptor-mediated cholesterol efflux from cells, we hypothesized that glycosylated HDL3 would have reduced ability to remove cholesterol from cells. HDL3 was glycosylated in vitro to achieve up to 40-50% reductions in free-lysine residues. Glycosylated HDL3 had a slightly greater ability than control HDL3 to sequester cholesterol directly from the plasma membrane, as predicted by changes in lipid composition. This process is independent of HDL-receptor binding and should not be influenced by reduced binding of HDL3. In contrast, efflux of intracellular cholesterol from cells, which is HDL-receptor dependent, was reduced 25-40%. The ability of glycosylated HDL3 to diminish cholesterol esterification was significantly reduced, indicating reduced net cholesterol efflux. Steady-state efflux of LDL-derived cholesterol was also markedly reduced. These findings suggest that nonenzymatically glycosylated HDL is functionally abnormal and might contribute to the accelerated development of atherosclerosis in patients with diabetes mellitus.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes Spectr.Home page
B. B. Dokken
The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids
Diabetes Spectr, July 1, 2008; 21(3): 160 - 165.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Lindstedt, J. Saarinen, N. Kalkkinen, H. Welgus, and P. T. Kovanen
Matrix Metalloproteinases-3, -7, and -12, but Not -9, Reduce High Density Lipoprotein-induced Cholesterol Efflux from Human Macrophage Foam Cells by Truncation of the Carboxyl Terminus of Apolipoprotein A-I. PARALLEL LOSSES OF PRE-beta PARTICLES AND THE HIGH AFFINITY COMPONENT OF EFFLUX
J. Biol. Chem., August 6, 1999; 274(32): 22627 - 22634.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Lee, A. von Eckardstein, L. Lindstedt, G. Assmann, and P. T. Kovanen
Depletion of Preß1LpA1 and LpA4 Particles by Mast Cell Chymase Reduces Cholesterol Efflux From Macrophage Foam Cells Induced by Plasma
Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 1066 - 1074.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
P. B. Duell, D. L. Wheaton, A. Shultz, and H. Nguyen
Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations
Clin. Chem., September 1, 1998; 44(9): 1931 - 1936.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. D. O'Brien, K. L. Olin, C. E. Alpers, W. Chiu, M. Ferguson, K. Hudkins, T. N. Wight, and A. Chait
Comparison of Apolipoprotein and Proteoglycan Deposits in Human Coronary Atherosclerotic Plaques : Colocalization of Biglycan With Apolipoproteins
Circulation, August 11, 1998; 98(6): 519 - 527.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. Igau, G. Castro, V. Clavey, C. Slomianny, R. Bresson, P. Drouin, J.-C. Fruchart, and C. Fievet
In Vivo Glucosylated LpA-I Subfraction : Evidence for Structural and Functional Alterations
Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2830 - 2836.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
E. Cavallero, F. Brites, B. Delfly, N. Nicolaiew, C. Decossin, C. De Geitere, J.-C. Fruchart, R. Wikinski, B. Jacotot, and G. Castro
Abnormal Reverse Cholesterol Transport in Controlled Type II Diabetic Patients : Studies on Fasting and Postprandial LpA-I Particles
Arterioscler. Thromb. Vasc. Biol., December 1, 1995; 15(12): 2130 - 2135.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1991 by the American Diabetes Association.